October 2022

PMPRB issues excessive price order on rare disease drug

By Kristin Wall & Christopher A. Guerreiro on October 5, 2022

The Patented Medicine Prices Review Board (PMPRB) has issued a decision that Procysbi (cysteamine bitartrate) is being sold at an “excessive” price. The PMPRB ordered the manufacturer, Horizon Pharma PLC (Horizon), to reduce its price and…

24-month stay extended under the PM(NOC) Regulations for late pleadings amendment

By Kristin Wall & Christopher A. Guerreiro on October 3, 2022

In a recent pleadings amendment motion under the Patented Medicines (Notice of Compliance) Regulations (the Regulations), the Federal Court gave the generic a choice: either (a) abandon proposed new grounds of invalidity or (b) accept that the scheduled trial…

Pharma in Brief

October 2022

PMPRB issues excessive price order on rare disease drug

24-month stay extended under the PM(NOC) Regulations for late pleadings amendment

About

Topics

Archives